Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to ...

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

CFO Beth Jantzen reported total revenues of $1.2 million for Q1 2025, a year-over-year increase driven by higher product revenue from DNA Tagging and increased isotopic testing services. Operating ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...

Moderna (NASDAQ:MRNA) shares fell ~5% in the premarket on Friday after the COVID-19 vaccine maker, with its Q4 2024 results, topped the consensus for revenue but missed Street forecasts for earnings ...

Moderna’s consensus price target has significantly declined from $119.26 to $47.5, indicating a cautious outlook from ...

The biotech giant reported a bigger-than-expected quarterly loss. Finance chief James Mock attributed the loss to a scale down.

Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for a canceled manufacturing contract.